Are nucleot(s)ide analogues a negative factor for HBsAg seroconversion in acute hepatitis B?

Basit Öğe Kaydı
dc.contributor.authorKeser, M. F.
dc.contributor.authorErdogan, M. A.
dc.contributor.authorYildirim, O.
dc.date.accessioned2026-04-04T13:30:44Z
dc.date.available2026-04-04T13:30:44Z
dc.date.issued2024
dc.departmentİnönü Üniversitesi
dc.description.abstractBackground and study aim: There are several studies comparing patients treated with lamivudine and those not given antiviral therapy in acute hepatitis B. Some of these studies showed that antiviral treatment significantly contributed to survival, whereas one other study suggested that antiviral treatment had no effect. The aim of this study was to investigate the efficacy of tenofovir disoproxil fumarate (TDF) therapy and its effect on HBsAg seroconversion in patients with acute viral hepatitis B. Patients and methods: The files of 126 patients who were under follow-up for acute HBV infection in the Department of Gastroenterology were analyzed retrospectively. Demographic data, molecular, ELISA, and biochemistry tests at the time of diagnosis and in the follow-up, period were evaluated using the hospital automation system. Results: The rate of chronicity of HBV was found to be higher in the TDF group than in the group without antiviral treatment. The rate of protective anti-HBs acquisition was found to be lower in the TDF group (p<0.05). Conclusion: Antiviral treatment with TDF in acute HBV infection may increase the rate of chronicity. It may reduce the development of natural immunity. Further studies are warranted. (Acta gastroenterol. belg., 2024, 87, 367-371).
dc.identifier.doi10.51821/87.3.12462
dc.identifier.endpage371
dc.identifier.issn1784-3227
dc.identifier.issue3
dc.identifier.orcid0000-0002-4524-9761
dc.identifier.pmid39411789
dc.identifier.scopus2-s2.0-85206542333
dc.identifier.scopusqualityN/A
dc.identifier.startpage367
dc.identifier.urihttps://doi.org/10.51821/87.3.12462
dc.identifier.urihttps://hdl.handle.net/11616/108349
dc.identifier.volume87
dc.identifier.wosWOS:001328358000001
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherUniv Catholique Louvain-Ucl
dc.relation.ispartofActa Gastro-Enterologica Belgica
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250329
dc.subjectacute hepatitis B
dc.subjectseroconversion
dc.subjectreactivation
dc.titleAre nucleot(s)ide analogues a negative factor for HBsAg seroconversion in acute hepatitis B?
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu